Patient perspectives on the use of oral corticosteroids in asthma

被引:0
|
作者
Winders, Tonya [1 ]
Fletcher, Monica [2 ]
Oppenheimer, John [3 ]
Howarth, Peter [4 ]
Antoun, Zeina Eid [5 ]
van der Molen, Thys [6 ]
Heaney, Liam G. [7 ]
Thomas, Mike [8 ]
机构
[1] Global Allergy & Airways Patient Platform, 10 Altgasse, A-1130 Vienna, Austria
[2] Univ Edinburgh, Edinburgh, Scotland
[3] Pulm & Allergy Associates, Bridgewater, NJ USA
[4] GSK, London, England
[5] ViiV Healthcare, London, Middx, England
[6] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, Groningen, Netherlands
[7] Queens Univ, Belfast, North Ireland
[8] Univ Southampton, Southampton, England
关键词
Asthma; oral corticosteroids; patients' perspective; medication adherence; education; patient-provider communication; ADVERSE EVENTS; PERCEPTIONS; MEPOLIZUMAB;
D O I
10.1080/02770903.2025.2466183
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
ObjectiveOral corticosteroids (OCS) are used to treat uncontrolled asthma, either as short rescue courses of treatment for severe disease exacerbations, or as long-term maintenance therapy in addition to other controller medications. Although the adverse events (AEs) associated with OCS are well understood by healthcare professionals (HCPs), the patient's perspective may be underappreciated. This review discusses the patient perspective on OCS use.Data SourcesA PubMed literature review was performed.Study SelectionArticles were selected to include those primarily containing data on patient perspectives on OCS use in asthma or other airway diseases, including qualitative and quantitative studies. Articles including only clinical data and those primarily focused on another indication were excluded. Additional articles meeting the criteria were permitted based on author knowledge and the bibliographies of systematic reviews on other topics.ResultsA total of 6066 articles were identified from the PubMed search; 111 were assessed more closely for eligibility. Fourteen articles were eventually selected by the reviewers for inclusion and confirmed by all authors. Several key themes were identified: (1) Key AEs were prominently reported by patients (including weight gain, skin thinning, known osteoporosis/osteopenia, and sleep/mood disturbances); (2) Impact of OCS on day-to-day lives; (3) Patient perceptions of OCS; (4) Effect of perceptions on treatment adherence.ConclusionHCPs should consider the impact that OCS have on their patients' wellbeing, including short courses. It is essential for HCPs to discuss the short and long-term risks of OCS with patients prior to initiation of treatment and consider alternatives for patients on long-term OCS.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Trends in oral corticosteroids use in severe asthma: a 14-year population-based study
    Mohsen Sadatsafavi
    Amir Khakban
    Hamid Tavakoli
    Solmaz Ehteshami-Afshar
    Larry D. Lynd
    J. Mark FitzGerald
    Respiratory Research, 22
  • [32] Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma
    Ramsahai, J. Michael
    Simpson, Jodie L.
    Cook, Alistair
    Gibson, Peter G.
    McDonald, Vanessa
    Grainge, Christopher
    Heaney, Liam G.
    Wark, Peter A. B.
    THORAX, 2023, : 868 - 874
  • [33] Use of Systemic Corticosteroids for Reasons Other than Asthma in Subjects with Asthma
    Watanabe, Keisuke
    Horita, Nobuyuki
    Hara, Yu
    Kobayashi, Nobuaki
    Kaneko, Takeshi
    RESPIRATION, 2021, : 109 - 115
  • [34] Red-flagging the prescribing of oral corticosteroids for people with asthma
    McDonald, Christine F.
    Worsnop, Christopher J.
    MEDICAL JOURNAL OF AUSTRALIA, 2020, 213 (07) : 313 - +
  • [35] Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes
    Namazy, Jennifer A.
    Murphy, Vanessa E.
    Powell, Heather
    Gibson, Peter G.
    Chambers, Christina
    Schatz, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (05) : 1082 - 1090
  • [36] Oral corticosteroids for asthma usually prescribed by non-specialists
    Van der Meer, Akke-Nynke
    De Jong, Kim
    Ferns, Michiel
    Krol, Marieke
    Widrich, Christine
    Ten Brinke, Anneke
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [37] Oral versus intravenous corticosteroids in adults hospitalised with acute asthma
    Cunnington, D
    Smith, N
    Steed, K
    Rosengarten, P
    Kelly, AM
    Teichtahl, H
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2005, 18 (03) : 207 - 212
  • [38] Overuse of Oral Corticosteroids in Asthma Is Often Underdiagnosed and Inadequately Addressed
    van der Meer, Akke-Nynke
    de Jong, Kim
    Ferns, Michiel
    Widrich, Christine
    ten Brinke, Anneke
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (08) : 2093 - 2098
  • [39] Intravenous versus oral corticosteroids for treatment of acute asthma exacerbations
    Fulco, PP
    Lone, AA
    Pugh, CB
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (04) : 565 - 570
  • [40] Oral corticosteroids in asthma exacerbations: Differences between patient-reported data and proxies from claims data
    Laforest, Laurent
    Dima, Alexandra L.
    Texier, Nathalie
    de Bruin, Marijn
    Hernandez, Gimena
    Nolin, Maeva
    van Ganse, Eric
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48